TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16443425
Drug: Methylphenidate 2
Normalized name: methylphenidate 25.9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 2 x 10 mg/day
Study: 15272642
Drug: Half-dose double-bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose double-bolus reteplase (2 x 5 IU) combined with abciximab
Study: 15272642
Drug: Full-dose reteplase
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose reteplase (2 x 10 IU)
Study: 9249892
Drug: Hypnotic suggestions
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestions
Study: 8142565
Drug: Mortality reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mortality reduction through early detection and treatment
Study: 3061181
Drug: Telenzepine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telenzepine 3 mg nightly
Study: 29211658
Drug: Letermovir (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir (480 mg per day or 240 mg per day in patients taking cyclosporine)
Study: 10801251
Drug: Quinidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (4 mg/kg)
Study: 9091708
Drug: DICpf pre‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: DICpf pre‐ and postop. in combination with dexamethasone‐21‐dihydrogenphosphate 0.1% eyedrops (DEXA)
Study: 9091708
Drug: Intraocular pressure
Normalized name: Brimonidine Tartrate 0.2% Ophthalmic drops, solution [Intraocular Pressure]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular pressure (IOP) management with carbachol 0.01% and dichlorphenamide (50 mg/d per os) until day 1 postoperatively
Study: 1315469
Drug: Lyophilized inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized inactivated hepatitis A vaccine (1.0 micrograms)
Study: 1315469
Drug: Lyophilized inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized inactivated hepatitis A vaccine (0.5 micrograms)
Study: 1315469
Drug: Lyophilized inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized inactivated hepatitis A vaccine (0.25 micrograms)
Study: 1315469
Drug: Lyophilized inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized inactivated hepatitis A vaccine (all dosage groups)
Study: 4006374
Drug: Disopyramide (D),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (D), 1.5 and 2 mg/kg iv
Study: 4006374
Drug: Dealkylated metabolite
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dealkylated metabolite (MND), 0.5 and 1.5 mg/kg iv
Study: 22261200
Drug: Non-PPI gastrointestinal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-PPI gastrointestinal drugs
Study: 22261200
Drug: No gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: No gastric therapy
Study: 17686110
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray 110 microg once daily (n = 605)
Study: 17686110
Drug: Vehicle placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle placebo nasal spray (n = 201)
Study: 15729552
Drug: Patient-provider relationship,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-provider relationship, facility setting, and information on diagnosis and treatment options
Study: 12196372
Drug: CE (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE (cisplatin 20 mg/m(2) and etoposide 100 mg/m(2) on days 1-3)
Study: 12196372
Drug: CCE (carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCE (carboplatin 200 mg/m(2) on day 1, cisplatin 30 mg/m(2) on days 2-3, etoposide 100 mg/m(2) on days 1-3)
Study: 7615269
Drug: 10 days'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days' treatment with metronidazole and eight weeks' treatment with colloidal bismuth subcitrate (CBS) (84 patients)
Study: 7615269
Drug: 10 days'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days' treatment with metronidazole placebo and eight weeks with CBS (73 patients)
Study: 7615269
Drug: open triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: open triple therapy (CBS 120 mg four times daily, amoxicillin 500 mg four times daily, and metronidazole 400 mg three times daily) given to patients with ulcer relapse
Study: 25380152
Drug: 10g cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g cocoa (0, 80, 200, 500 and 800 mg cocoa flavonoids/day)
Study: 25380152
Drug: 10g cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g cocoa (80 mg cocoa flavonoids/day)
Study: 23839178
Drug: 3mg Drospirenone/0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg Drospirenone/0.02 mg Ethinyl Estradiol
Study: 14745876
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid complex (ABLC) 2.5 mg/kg intravenously 3 times weekly
Study: 14745876
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L-AmB) 3 mg/kg 3 times weekly
Study: 11673080
Drug: Cisplatin‐based combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin‐based combination chemotherapy
Study: 8988721
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 500 mg/body weight/day for 7 days preoperatively
Study: 29043567
Drug: S-1 chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 chemotherapy
Study: 29043567
Drug: Taxane therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane therapies
Study: 27895474
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (1.5 g/day for 10 weeks)
Study: 20106684
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (Jarsin) administered t.i.d. for 15 days
Study: 20106684
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered t.i.d. for 15 days
Study: 18799995
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg x kg(‐1) body mass)
Study: 11850269
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) at 2 mg/kg body weight
Study: 11850269
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate at 0.6 mg/kg body weight
Study: 7627761
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia with adrenaline (4 ml lidocaine 2% and 250 IU hyaluronidase with adrenaline)
Study: 7627761
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia without adrenaline (4 ml lidocaine 2% and 250 IU hyaluronidase without adrenaline)
Study: 1957103
Drug: Slow-release oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release oral salbutamol (SRS) 8 mg b.d.
Study: 7138719
Drug: Extradural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural morphine 0.05 mg kg‐1
Study: 7138719
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 0.1 mg kg‐1
Study: 30073390
Drug: hu14.18-IL2 immunocytokine
Approvals — FDA: no, EMA: no, PMDA: no
Description: hu14.18-IL2 immunocytokine (IC) at 6 mg/m2/day i.v. on days 1, 2, and 3 of each 28-day course, 3 courses total.
Study: 17714352
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate magistral preparation
Study: 16516075
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg clopidogrel pre-treatment for >=15 hours
Study: 11004030
Drug: perflubron emulsion
Normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: perflubron emulsion at 1.2 g PFC/kg
Study: 11004030
Drug: perflubron emulsion
Normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: perflubron emulsion at 1.8 g PFC/kg
Study: 11004030
Drug: saline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline (3 mL/kg) control
Study: 23057417
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment (IFN)
Study: 23057417
Drug: No Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Interferon treatment
Study: 15580451
Drug: 685-nm low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 685-nm low level laser therapy
Study: 12380631
Drug: Naproxen 400
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 400 mg
Study: 12380631
Drug: Naproxen 200
Normalized name: naproxen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 200 mg
Study: 12380631
Drug: Naproxen 400
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 400 mg and 200 mg
Study: 10428106
Drug: Two-drug combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug combinations of Zidovudine and Didanosine
Study: 22835011
Drug: High-level FK778
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-level FK778 (H) 4 x 600 mg/day (4 days) followed by 120 mg/day
Study: 22835011
Drug: Mid-level FK778
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-level FK778 (M) 3 x 600 mg/day (3 days) followed by 110 mg/day
Study: 22835011
Drug: Low-level FK778
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-level FK778 (L) 2 x 600 mg/day (2 days) followed by 100 mg/day
Study: 22835011
Drug: MMF 1
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF 1 g/day (Control)
Study: 19238303
Drug: Genistein (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genistein (54 mg/die)
Study: 9676147
Drug: Karaoke therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karaoke therapy
Study: 31600271
Drug: Can do
Approvals — FDA: no, EMA: no, PMDA: no
Description: Can do treatment (CDT)
Study: 28854538
Drug: Dexmedetomidine delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine delivered via target-controlled infusion
Study: 25599735
Drug: Atorvastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 20 mg/d
Study: 25599735
Drug: Atorvastatin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin with NER, 500 mg/d
Study: 12756424
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine tooth patch (NTP)
Study: 12756424
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine tooth patch (NTP)
Study: 12756424
Drug: 4.3 mg
Normalized name: menthol 4.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.3 mg nicotine tooth patch (NTP)
Study: 10319446
Drug: Individually administered
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually administered mood induction procedure
Study: 10319446
Drug: Group administered
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group administered mood induction procedure
Study: 81586
Drug: Supervised toothbrushing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised toothbrushing every second week during the school year, using a disclosing solution.
Study: 31196132
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus clindamycin for 7 days
Study: 31196132
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (flucloxacillin/cefazolin for MSSA; vancomycin/daptomycin for MRSA)
Study: 28327804
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (1 mg/kg/day for 14 days)
Study: 19179026
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated estrogen 0.625mg/day
Study: 19179026
Drug: Intranasal 300microg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 300microg/day estradiol hemihidrate
Study: 19179026
Drug: Percutaneous gel
Normalized name: ALCOHOL 62 mL in 100 mL PERCUTANEOUS GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous gel 1.5mg/day estradiol hemihidrate
Study: 11440787
Drug: Bretschenider solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretschenider solution (HTK)
Study: 7972649
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy with respiratory feedback (RFB)
Study: 2656335
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg famotidine twice daily
Study: 28600210
Drug: Accelerated epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated epirubicin (100 mg/m2 every 2 weeks with 6 mg pegfilgrastim on day 2)
Study: 28600210
Drug: Standard epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard epirubicin (100 mg/m2 every 3 weeks)
Study: 28600210
Drug: Capecitabine (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (2500 mg/m2, 1250 mg/m2 given twice daily on days 1-14 of each cycle)
Study: 28600210
Drug: CMF (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (600 mg/m2 cyclophosphamide, 40 mg/m2 methotrexate, 600 mg/m2 fluorouracil)
Study: 9786563
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg, two capsules)
Study: 9786563
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two identical appearing capsules)
Study: 8156351
Drug: Levovist 300
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levovist 300 mg/ml (10 ml intravenous injection)
Study: 2845188
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (single dose and long term administration)
Study: 27085768
Drug: Social cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social cognitive theory‐based weight‐management treatments emphasizing physical activity‐derived self‐regulation (n=53)
Study: 25521188
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g SQ-LNS with varying contents of zinc
Study: 25521188
Drug: Dispersible tablet
Normalized name: Aspirin 75 mg orodispersible tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablet containing 0 or 5 mg zinc
Study: 23764385
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (mean blood level 0.67 mEq/L)
Study: 21343159
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 2% (1.5 mg kg(‐1) bolus at induction followed by 2.0 mg kg(‐1) h(‐1) infusion)
Study: 17609296
Drug: Testosterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (200 mg every 2 weeks by intramuscular injection with placebo pill daily)
Study: 17609296
Drug: Testosterone plus
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone plus Finasteride (200 mg of T every 2 weeks by intramuscular injection with 5 mg of finasteride daily)
Study: 17609296
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo injections and pills)
Study: 15728645
Drug: Acute insulin-glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute insulin-glucose infusion followed by insulin-based long-term glucose control (Group 1)
Study: 15728645
Drug: Insulin-glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-glucose infusion followed by standard glucose control (Group 2)
Study: 2696506
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plus fentanyl 75 mcg
Study: 1104246
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gluconate solution, twice a day
Study: 21838784
Drug: itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: itraconazole 100 mg
Study: 21838784
Drug: gemfibrozil-itraconazole combination
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil-itraconazole combination
Study: 20578781
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus oral antidiabetes drugs (OADs)
Study: 20578781
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin only
Study: 16087029
Drug: Dexamethasone inner
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone inner ear perfusion (4 mg/mL)
Study: 12600856
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (10 mg Fe, 5 d/wk for 6 mo)
Study: 12600856
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (10 mg Zn, 5 d/wk for 6 mo)
Study: 12600856
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (2.4 mg beta-carotene, 5 d/wk for 6 mo)
Study: 12600856
Drug: Iron +
Normalized name: Celebrate Iron + C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron + Zinc supplementation (10 mg each, 5 d/wk for 6 mo)
Study: 11214351
Drug: Vitamin A,
Normalized name: Vitamin A, D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A, 3 mg retinol equivalent/day
Study: 8626351
Drug: Valproate (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (given twice daily)
Study: 8626351
Drug: Placebo (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (given twice daily)
Study: 6429875
Drug: Conventional Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Oral Nutritional Support (CN)
Study: 24456057
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy modalities
Study: 24456057
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Virtual reality and Standard physical therapy)
Study: 22689471
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL FV-puree-based drink (FVPD)
Study: 10609985
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate 15 mg/5 mL
Study: 10609985
Drug: Trimeprazine tartrate
Normalized name: Trimeprazine Tartrate
DrugBank: Alimemazine (DB01246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimeprazine tartrate 30 mg/5 mL
Study: 8538895
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.5 mg/kg
Study: 8538895
Drug: Rectal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal midazolam 0.5 mg/kg
Study: 1650015
Drug: GM-CSF during
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF during chemotherapy
Study: 1650015
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without GM-CSF
Study: 6345596
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen (chlorthalidone 25 mg/day, oxdralazine 20 mg/day, propranolol 40 mg/day)
Study: 6345596
Drug: Double regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double regimen (chlorthalidone 25 mg/day, propranolol 103 mg/day)
Study: 6345596
Drug: Triple regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple regimen (chlorthalidone 25 mg/day, oxdralazine 56 mg/day, propranolol 112 mg/day)
Study: 6345596
Drug: Double regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double regimen (chlorthalidone 25 mg/day, propranolol 222 mg/day)
Study: 23203821
Drug: IFN‐K (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐K (30 μg, 60 μg, 120 μg, or 240 μg)
Study: 19506491
Drug: Pressure therapy
Normalized name: AerobiKA Oscillating Positive Expiratory Pressure Therapy System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure therapy (PT) group
Study: 16790659
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of 1% preservative free 2‐chloroprocaine
Study: 16790659
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of 1% preservative free 2‐chloroprocaine
Study: 16790659
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of 1% preservative free 2‐chloroprocaine
Study: 8418720
Drug: Caudal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal nerve block with 0.25% bupivacaine, 0.75 mL/kg (group I)
Study: 8418720
Drug: Caudal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal nerve block with 0.25% bupivacaine and 1:200,000 epinephrine, 0.75 mL/kg (group II)